The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yee, C.
Right arrow Articles by Greenberg, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yee, C.
Right arrow Articles by Greenberg, P. D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Melanoma

The Journal of Immunology, Vol 157, Issue 9 4079-4086, Copyright © 1996 by American Association of Immunologists

ARTICLES

Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus

C Yee, MJ Gilbert, SR Riddell, VG Brichard, A Fefer, JA Thompson, T Boon and PD Greenberg
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.

The identification of Ags expressed by tumor cells and recognized by autologous T cells has led to the prospect of treating cancer by adoptive transfer of tumor-reactive T cells selected for Ag specificity. Tyrosinase is an Ag expressed by normal melanocytes as well as melanoma cells for which responses by autologous T cells have been detected. To evaluate the frequency with which tyrosinase-specific T cells can be isolated from melanoma patients for potential use in therapy, a recombinant vaccinia virus expressing tyrosinase was constructed for infection of autologous APCs that could be used to stimulate T cells reactive with this protein. Eight patients were studied, with peripheral blood serving as the source of both responder T cells and autologous APCs. Tyrosinase-specific CD8+ CTL clones were isolated from five of the eight patients with melanoma. The tyrosinase- specific CTL generated in this manner recognized autologous tumor cells as well as targets expressing the recombinant virus vector. CTL clones from three of the individuals were restricted to HLA-A28, -B8, and - B60, which have not previously been identified as alleles that can present immunogenic tyrosinase peptides. Tyrosinase-specific CD4+ T cell clones were isolated from six of the eight patients by stimulation with autologous APCs infected with recombinant vaccinia virus, and all these CD4+ clones were capable of recognizing autologous tumor cells. These studies demonstrate a high prevalence of CD4+ and CD8+ tyrosinase- specific responses in peripheral blood and support the feasibility of using peripheral blood to generate T cells for tumor therapy without the requirement for isolating T cells that have infiltrated tumor sites.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Deola, M. C. Panelli, D. Maric, S. Selleri, N. I. Dmitrieva, C. Y. Voss, H. Klein, D. Stroncek, E. Wang, and F. M. Marincola
Helper B Cells Promote Cytotoxic T Cell Survival and Proliferation Independently of Antigen Presentation through CD27/CD70 Interactions
J. Immunol., February 1, 2008; 180(3): 1362 - 1372.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Lepage and R. Lapointe
Melanosomal Targeting Sequences from gp100 Are Essential for MHC Class II-Restricted Endogenous Epitope Presentation and Mobilization to Endosomal Compartments
Cancer Res., February 15, 2006; 66(4): 2423 - 2432.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Maia, W. N. Haining, S. Ansen, Z. Xia, S. A. Armstrong, N. P. Seth, P. Ghia, M. L. den Boer, R. Pieters, S. E. Sallan, et al.
Gene Expression Profiling Identifies BAX-{delta} as a Novel Tumor Antigen in Acute Lymphoblastic Leukemia
Cancer Res., November 1, 2005; 65(21): 10050 - 10058.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al.
Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma
Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. R. Parkhurst, J. P. Riley, T. Igarashi, Y. Li, P. F. Robbins, and S. A. Rosenberg
Immunization of Patients with the hTERT:540-548 Peptide Induces Peptide-Reactive T Lymphocytes That Do Not Recognize Tumors Endogenously Expressing Telomerase
Clin. Cancer Res., July 15, 2004; 10(14): 4688 - 4698.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, and R. W. Dutton
Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses
J. Immunol., February 1, 2004; 172(3): 1380 - 1390.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, J. C. Hylind, and R. W. Dutton
Effector Cell-Derived Lymphotoxin {alpha} and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases
Cancer Res., January 1, 2004; 64(1): 406 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
K. Matsui, L. A. O'Mara, and P. M. Allen
Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy
Int. Immunol., July 1, 2003; 15(7): 797 - 805.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Crittenden, M. Gough, J. Chester, T. Kottke, J. Thompson, A. Ruchatz, T. Clackson, F. L. Cosset, H. Chong, R. M. Diaz, et al.
Pharmacologically Regulated Production of Targeted Retrovirus from T Cells for Systemic Antitumor Gene Therapy
Cancer Res., June 15, 2003; 63(12): 3173 - 3180.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
H. E. Heslop, F. K. Stevenson, and J. J. Molldrem
Immunotherapy of Hematologic Malignancy
Hematology, January 1, 2003; 2003(1): 331 - 349.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Hanabuchi, T. Ohashi, Y. Koya, H. Kato, A. Hasegawa, F. Takemura, T. Masuda, and M. Kannagi
Regression of Human T-cell Leukemia Virus Type I (HTLV-I)-Associated Lymphomas in a Rat Model: Peptide-Induced T-Cell Immunity
J Natl Cancer Inst, December 5, 2001; 93(23): 1775 - 1783.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Meyer zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard
The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells
J. Immunol., August 1, 2001; 167(3): 1712 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Bonini, S. P. Lee, S. R. Riddell, and P. D. Greenberg
Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+ and CD8+ T Cells
J. Immunol., April 15, 2001; 166(8): 5250 - 5257.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Dalyot-Herman, O. F. Bathe, and T. R. Malek
Reversal of CD8+ T Cell Ignorance and Induction of Anti-Tumor Immunity by Peptide-Pulsed APC
J. Immunol., December 15, 2000; 165(12): 6731 - 6737.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Meyer zum Buschenfelde, N. Nicklisch, S. Rose-John, C. Peschel, and H. Bernhard
Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells
J. Immunol., October 1, 2000; 165(7): 4133 - 4140.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Gnjatic, Y. Nagata, E. Jager, E. Stockert, S. Shankara, B. L. Roberts, G. P. Mazzara, S. Y. Lee, P. R. Dunbar, B. Dupont, et al.
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele
PNAS, September 26, 2000; 97(20): 10917 - 10922.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Yang, D. Kittlesen, C. L. Slingluff Jr., C. E. Vervaert, H. F. Seigler, and T. L. Darrow
Dendritic Cells Infected with a Vaccinia Vector Carrying the Human gp100 Gene Simultaneously Present Multiple Specificities and Elicit High-Affinity T Cells Reactive to Multiple Epitopes and Restricted by HLA-A2 and -A3
J. Immunol., April 15, 2000; 164(8): 4204 - 4211.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. M. Zarour, J. M. Kirkwood, L. S. Kierstead, W. Herr, V. Brusic, C. L. Slingluff Jr., J. Sidney, A. Sette, and W. J. Storkus
Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells
PNAS, January 4, 2000; 97(1): 400 - 405.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Wang, S. Bartido, G. Yang, J. Qin, Y. Moroi, K. S. Panageas, J. J. Lewis, and A. N. Houghton
A Role for a Melanosome Transport Signal in Accessing the MHC Class II Presentation Pathway and in Eliciting CD4+ T Cell Responses
J. Immunol., December 1, 1999; 163(11): 5820 - 5826.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Drexler, E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter
Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo
Cancer Res., October 1, 1999; 59(19): 4955 - 4963.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Valmori, M. J. Pittet, D. Rimoldi, D. Lienard, R. Dunbar, V. Cerundolo, F. Lejeune, J.-C. Cerottini, and P. Romero
An Antigen-targeted Approach to Adoptive Transfer Therapy of Cancer
Cancer Res., May 1, 1999; 59(9): 2167 - 2173.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
S. Manici, T. Sturniolo, M. A. Imro, J. Hammer, F. Sinigaglia, C. Noppen, G. Spagnoli, B. Mazzi, M. Bellone, P. Dellabona, et al.
Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11
J. Exp. Med., March 1, 1999; 189(5): 871 - 876.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Yee, P. A. Savage, P. P. Lee, M. M. Davis, and P. D. Greenberg
Isolation of High Avidity Melanoma-Reactive CTL from Heterogeneous Populations Using Peptide-MHC Tetramers
J. Immunol., February 15, 1999; 162(4): 2227 - 2234.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. H. Butterfield, S. M. Jilani, N. G. Chakraborty, L. A. Bui, A. Ribas, V. B. Dissette, R. Lau, S. C. Gamradt, J. A. Glaspy, W. H. McBride, et al.
Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus
J. Immunol., November 15, 1998; 161(10): 5607 - 5613.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. P. Bettinotti, C. J. Kim, K.-H. Lee, M. Roden, J. N. Cormier, M. Panelli, K. K. Parker, and F. M. Marincola
Stringent Allele/Epitope Requirements for MART-1/Melan A Immunodominance: Implications for Peptide-Based Immunotherapy
J. Immunol., July 15, 1998; 161(2): 877 - 889.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Tuting, C. C. Wilson, D. M. Martin, Y. L. Kasamon, J. Rowles, D. I. Ma, C. L. Slingluff Jr., S. N. Wagner, P. van der Bruggen, J. Baar, et al.
Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN-{alpha}
J. Immunol., February 1, 1998; 160(3): 1139 - 1147.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
E. Jager, Y.-T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, et al.
Simultaneous Humoral and Cellular Immune Response against Cancer-Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2-binding Peptide Epitopes
J. Exp. Med., January 19, 1998; 187(2): 265 - 270.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. J. Diamond, J. York, J.-Y. Sun, C. L. Wright, and S. J. Forman
Development of a Candidate HLA A*0201 Restricted Peptide-Based Vaccine Against Human Cytomegalovirus Infection
Blood, September 1, 1997; 90(5): 1751 - 1767.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1996 by The American Association of Immunologists, Inc. All rights reserved.